Immupharma Share Discussion Threads

[qazwsxedc69] 07/12/2017 08:59

ewads - It is actually quite impressive to get so much wrong in such a short post.

[hottingup] 07/12/2017 08:57

No chance of that. Results so far easily beat GSK's Benlysta on safety and efficacy.

[ewads] 07/12/2017 08:54

On average results, IMM will be forced to go it alone, so funding will be required mid 2018

[professor bang bang] 07/12/2017 08:48

IMM will probably be taken over after the Phase III results next month.

[hamhamham1] 07/12/2017 07:15

Route to market -
Lupuzor™ can be marketed by:
• A global licensee, offering ImmuPharma royalties on sales (similar to
Cephalon deal)
• ImmuPharma controlling manufacture through Polypeptide* using local
distributors, retaining a higher margin
• Being acquired by Big Pharma

[hamhamham1] 07/12/2017 07:04

link removed?? - google "immupharma 2016 feb presentation" and see the proactiveinvestors pdf in google results (page 16). You guys probably already discussed this no doubt a thousand times :)

[hamhamham1] 07/12/2017 07:00

ahh, been documented before....(page 16)....
[...]

[hamhamham1] 07/12/2017 06:47

Where to manufacture? So if Immupharma are preparing early stages of manufacturing process, will they be using Polypeptide to make the drug? If so, isn't this the company co founded by Immupharma's resident brainbox Sylviane Muller? Would this have any affect on any partnering? I presume she still has interests in Polypeptide?
"Muller has co-founded two companies based on her discoveries: Neosystem (now Polypeptide France) in 1986 and ImmuPharma in 2002. "
- hxxp://www.epo.org/learning-events/european-inventor/finalists/2017/muller.html
- hxxps://www.polypeptide.com/polypeptide-lab-strasbourg-france/p54.html

[ny boy] 06/12/2017 20:58

Maybe let’s just start getting above 150/175p for starters, any big takeout number later next year will be fine for me, tick tock.

[l0ngterm] 06/12/2017 20:52

Divisionmad: no shocks from that based upon your moniker..Now stop forming a clique and justify?

[divmad] 06/12/2017 20:45

0.5p to £400 more likely. Covers all bases.

[l0ngterm] 06/12/2017 20:43

Spawny: you doubt my £2.00 to £400.00 range.You doubter, I can 100% guarantee upon success that it will fall between this range.Now please put your case forward as to why I am wrong.I bet you can't :-)

[spawny100] 06/12/2017 20:32

Lol £400 per share now? That's a new all time high prediction I think!

[l0ngterm] 06/12/2017 20:17

So folks:Back to 200-500p near term.And mid term 1500-40000+.Not long to find out Hit thumbs up if we can wait and see, it's not long to go.

[hottingup] 06/12/2017 20:15

Pre Phase 3 you tend to get drug deals but post Phase 3 it tends to be takeovers, so the probability is that IMM will be bought out and it will likely be £40+, as already established by sector precedents.

[scoredagain] 06/12/2017 19:12

Meant of course i would love it happen

[scoredagain] 06/12/2017 19:11

Ham Ham I always said 1.50 up and to results we not far out now , And if all goes to plan 12 to 15 pound a share within 2 years , That i think is being realistic unlike some on here and at 15 pound a share we would have a very large market cap Dont get me wrong investors but i cant see 100 pound a share .Of i would love it to happen but it wont

[professor bang bang] 06/12/2017 19:00

Several of those top 20 companies will be interested in Lupuzor hamham. I have been researching this and other things connected to the whole platform.

[ny boy] 06/12/2017 18:25

Lots of buys before the close, earlier, some weak holders got shafted again, they were nicely seduced lol

[l0ngterm] 06/12/2017 18:20

To expand further, we are currently looking at point/specific solutions. The more I research, the more is published about how this mechanism could alleviate(note not cure) other diseases and challenges.

[l0ngterm] 06/12/2017 18:15

How many of those outstanding generate revenue from RA?As they could buy out to maximise their position in RA alone?It's all up for grabs.. no matter which way you cut the data.If IMM prove an immodulator for the Immune system, that reduces flares, swelling etc. then think of the combinations.. I have less confidences in lupus being the golden goose, and getting more convinced about the broader impact, and what success means.But Lupus, provides one piece of evidence in a larger market.

[hamhamham1] 06/12/2017 18:01

Looking online at the current and pipeine therapies, this still over 10 or the top 20 pharmas without a product for Lupus? I wonder if one of the ones which are missing from the list below will be a likely partner as a prospective partner wouldn't want to double its efforts?

Marketed Therapies -
Benlysta (belimumab; HGS/GSK)
Rituxan/MabThera (rituximab; Roche – OFF LABEL)

Pipeline Therapies -
Anifrolumab (BMZ/AstraZeneca)
Forigerimod (ImmunPharma)
Abatacept (BMS)
Voclosporin (Aurinia Pharma)
BIIB 059 (Biogen)
Obinutuzumab (Roche)
Dapirolizumab pegol (UCB)
Ustekinumab (Janssen Biotech)
Theralizumab (TheraMab)
Baricitinib (Eli Lilly)

Top 20 Pharmas by revenue -


Current / Pipeline list -
hxxps://www.prnewswire.com/news-releases/systemic-lupus-erythematosus-sle-kol-insight-2017-300550427.html

[l0ngterm] 06/12/2017 17:51

The updates varied between start and end of month. But the general consensus was 166 should be through the trial by now.This may increase, as we have slipped into December.But I would expect an rns out in December folks.

[hottingup] 06/12/2017 17:30

By my reckoning the last patient receives their last dose in the Phase 3 trial this month, followed by their last evaluation 28 days later in January, with release of results shortly afterwards.